Aktis Oncology Announces Pricing of its…

SAN CARLOS, Calif.--Nov 10, 2025--CuraSen Therapeutics, Inc., a biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced encouraging results from a Phase 1 study with CuraAX (CST-3056). Data were presented by Gabriel Vargas, MD, PhD, chief medical officer, CuraSen Therapeutics, in both an oral and poster presentation at the 36^th International Symposium on the Autonomic Nervous System, held November 5-8 in Clearwater Beach, FL.

SAN CARLOS, Calif.--10/23/25--CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced dosing of the first patient with CuraAX (CST-3056) in a Phase 2a proof-of-concept trial in neurogenic orthostatic hypotension (nOH). nOH is a serious condition characterized by a sudden drop in blood pressure when a person moves from sitting to standing, or from a supine position to sitting, that leads to debilitating dizziness, fainting, falls, hospitalizations and cognitive impairment due to reduced blood flow to the brain.

SAN CARLOS, Calif.--February 20, 2025--CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral, rapid onset, small molecule drugs to treat psychiatric and neurodegenerative diseases, announced today that it has treated its first subject with CuraAX, an alpha-1A adrenoceptor agonist, in a Phase 1 clinical trial. The company is developing CuraAX for patients with neurogenic orthostatic hypotension (nOH). Neurogenic orthostatic hypotension is a condition characterized by a significant, sudden drop in blood pressure upon standing, resulting in debilitating dizziness, fainting and cognitive impairment, due to inadequate blood flow to the brain. CuraAX is also expected to benefit cognition in patients with a range of neurologic conditions.